HRAS and cancer: In line with these combined effects, TCGA (“The Cancer Genome Atlas”) data analysis using the “SurvExpress”-Biomarker validation for cancer gene expression database [40] revealed that stratification into low risk (n = 269) and high risk (n = 92) patient groups (based on prognostic index) shows reduced overall survival in the high risk group and marked overexpression of both PLK1 and HRAS (Figure 6B).